Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | CFTR | P13569 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5383680 | 1.00 | ADORA2B (0.38) | ADORA2BADORA2AKCNA5HSD17B10MAPT | |
| SCHEMBL5384192 | 1.00 | ADORA2B (0.38) | ADORA2BADORA2AKCNA5HSD17B10MAPT | |
| SCHEMBL14428529 | 0.86 | ADORA2B (0.39) | ADORA2BADORA2AKCNA5HSD17B10MAPT | |
| SCHEMBL5383565 | 0.81 | ADORA2B (0.40) | ADORA2BADORA2AKCNA5HSD17B10MAPT | |
| SCHEMBL5378828 | 0.76 | SLC6A4 (0.42) | KCNA5HSD17B10MAPTTSHRSLC6A2 | |
| SCHEMBL4048996 | 0.75 | GAA (0.47) | KCNA5HSD17B10ALDH1A1KDM4E | |
| SCHEMBL14428530 | 0.75 | CYP3A4 (0.36) | ADORA2BADORA2AKCNA5HSD17B10SLC6A2 | |
| SCHEMBL31382691 | 0.74 | OPRL1 (0.39) | ADORA2ACSF1ROPRL1 | |
| SCHEMBL6689152 | 0.72 | CHRNA7 (0.38) | KCNA5HSD17B10MAPTTSHRSLC6A2 | |
| SCHEMBL6688396 | 0.72 | CHRNA7 (0.38) | KCNA5HSD17B10MAPTTSHRSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185086-A1 | Pharmaceutical Compositions and Methods for Effecting Dopamine Release | BENCHERIF MEROUANE | 2007-08-09 | — | — | US | disclosed |
| US-7214686-B2 | Pharmaceutical compositions and methods for effecting dopamine release | TARGACEPT, INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-20040220214-A1 | Pharmaceutical compositions and methods for effecting dopamine release | TARGACEPT, INC. | 2004-11-04 | — | — | US | disclosed |
| EP-0994875-B1 | 3-PYRIDYL-1-AZABICYCLOALKANE DERIVATIVES FOR PREVENTION AND TREATMENT OF CNS DISORDERS | TARGACEPT INC (US) | 2004-03-10 | — | — | EP | disclosed |
| US-6624173-B1 | Characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia) treated by | TARGACEPT, INC. | 2003-09-23 | — | — | US | disclosed |
| US-6525065-B1 | Central nervous system disorders; administering an endo or exo form of a 1-aza-2-(3-pyridyl)bicyclo(2.2.1)heptane, or a 1-aza-7-(3-pyridyl)bicyclo(3.2.2) nonane, or a 1-aza-2-(3-pyridyl)bicyclo(2.2.2)octane | TARGACEPT, INC. | 2003-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220214-A1 | Pharmaceutical compositions and methods for effecting dopamine release | COMT, SLC6A3, PARK7 | ADORA2B 95/4885ADORA2A 22/4885KCNA5 2905/4885 |
| US-20070185086-A1 | Pharmaceutical Compositions and Methods for Effecting Dopamine Release | COMT, SLC6A3, HTR2A | ADORA2B 202/4885ADORA2A 44/4885KCNA5 3412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.